—Ms. Quigley's Broad Biotechnology Industry
Experience Encompasses Leadership Positions in Executive
Management, Operations and Legal Affairs—
TEL
AVIV, Israel, June 21,
2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibrotic and inflammatory diseases with high unmet need, today
announced that Jill M. Quigley, JD,
has been appointed to the Chemomab board of directors. Ms. Quigley
brings more than 20 years of biotechnology industry leadership
experience encompassing executive management, corporate operations,
legal affairs, financings, and board membership.
Dale Pfost, PhD, Chairman and
Chief Executive Officer of Chemomab, commented, "We are delighted
to welcome Jill Quigley to our board
of directors. She brings an exceptionally well-rounded suite of
biotechnology skills and experience to Chemomab. Building on her
initial expertise in legal affairs, Jill broadened her capabilities
and experience, ultimately serving as head of operations and chief
executive of biotechnology firms developing important innovative
products for rare diseases. She has worked extensively with public
companies, established domestic and international operations,
helped lead major financing rounds and served as a senior executive
at a U.S.-Israeli biopharmaceutical firm. We look forward to her
many contributions as a Chemomab director."
"Chemomab is at an exciting time in its development, as it
advances its novel antibody CM-101 in clinical trials for primary
sclerosing cholangitis and prepares to launch a Phase 2 trial in
systemic sclerosis, two potentially fatal rare diseases in urgent
need of better therapies," said Ms. Quigley. "I have been impressed
by the rigor and novelty of the company's science and the strength
of its management. I look forward to working with my fellow
directors and the Chemomab team to help the company realize its
goal of developing first-in-class disease-modifying therapies that
make a major difference in the lives of patients."
Until December 2021, Ms. Quigley
was Chief Operating Officer at Passage Bio, a publicly traded gene
therapy company. Previously, she served as Chief Executive Officer
and General Counsel of Nutrinia, a developer of novel treatments
for rare gastrointestinal diseases. Earlier, Ms. Quigley served as
Senior Counsel at NPS Pharmaceuticals, a publicly traded
biotechnology company that was acquired by Shire; as Corporate
Counsel for Pharmasset, a publicly traded biotechnology firm that
was acquired by Gilead Sciences; and as Assistant Corporate Counsel
for publicly traded Integra Life Sciences. Earlier in her career
she was an Associate with the law firm of Dechert LLP. Ms. Quigley
holds a BA degree from American
University and a JD from Rutgers
School of Law.
Ms. Quigley, who is filling an open position on the Chemomab
board, will serve on Chemomab's Audit Committee. She currently is
also a member of the board of directors of publicly traded Terns
Pharmaceuticals, where she is Chair of the Audit Committee.
About Chemomab
Therapeutics
Chemomab is a clinical stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information,
visit chemomab.com.
Forward Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: risks related to Chemomab's ability to effectively
implement the revised clinical strategy and its ability to achieve
the anticipated results; risks related to the projections and
associated benefits in pursuing the contemplated changes to the
clinical strategy; risks associated with the ongoing transitions of
certain of our executive officers, including Chemomab's new Chief
Executive Officer; the uncertain and time-consuming regulatory
approval process; risks related to Chemomab's ability to correctly
manage its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials including any potential delays associated with
Chemomab's contemplated revised clinical strategy; the timing of
any planned investigational new drug application or new drug
application; Chemomab's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Chemomab's product candidates; Chemomab's commercialization,
marketing and manufacturing capabilities and strategy; Chemomab's
ability to protect its intellectual property position; and the
requirement for additional capital to continue to advance these
product candidates, which may not be available on favorable terms
or at all. Additional risks and uncertainties relating to Chemomab
and its business can be found under the caption "Risk Factors" and
elsewhere in Chemomab's filings and reports with the SEC. Chemomab
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Chemomab's expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based, except to the
extent required by applicable law.
Contacts:
Media:
Barbara Lindheim
Chemomab
Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
Investor Relations:
Irina
Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-appoints-jill-m-quigley-jd-to-its-board-of-directors-301571517.html
SOURCE Chemomab Therapeutics, Ltd.